Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Mind Medicine (MindMed) Inc. - Common Shares (NQ:MNMD)

15.02 UNCHANGED
Last Price Updated: 4:00 PM EST, Jan 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Mind Medicine (MindMed) Inc. - Common Shares

< Previous 1 2 3 4 5 6 Next >
News headline image
MindMed to be Included in Russell 2000® and Russell 3000® Indexes
From Mind Medicine Inc.
Via Business Wire
News headline image
MindMed to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
From Mind Medicine Inc.
Via Business Wire
News headline image
MindMed Announces Constructive End-of-Phase 2 Meeting with U.S. FDA for MM120 in Generalized Anxiety Disorder (GAD)
From Mind Medicine
Via Business Wire
News headline image
MindMed to Participate in June Conferences
From Mind Medicine Inc.
Via Business Wire
News headline image
MindMed to Participate at May Investor Conferences
From MindMed
Via Business Wire
News headline image
New Studies Presented at the International Society for Health Economics and Outcomes Research Meeting (ISPOR 24) Show Growing Burden and Impact of Generalized Anxiety Disorder (GAD) in the US
From Mind Medicine (MindMed) Inc.
Via Business Wire
News headline image
MindMed Reports First Quarter 2024 Financial Results and Business Updates
From MindMed
Via Business Wire
News headline image
MindMed Presents Phase 2b Study of MM120 for Generalized Anxiety Disorder (GAD) at American Psychiatric Association (APA) Annual Meeting in New York
From MindMed
Via Business Wire
News headline image
MindMed to Host Conference Call and Webcast to Discuss First Quarter 2024 Financial Results and Provide Business Update
From MindMed
Via Business Wire
News headline image
MindMed to Present at Upcoming May Medical Conferences
From MindMed
Via Business Wire
News headline image
MindMed to Present at Upcoming April Medical Conferences
From Mind Medicine
Via Business Wire
News headline image
MindMed Announces Voluntary Delisting from Cboe Canada
From MindMed
Via Business Wire
The Next Great Biotech Boom Has Arrived
EQNX::TICKER_START (NYSE:JNJ),(NASDAQ:CMPS),(NASDAQ:MNMD),(NASDAQ:ATAI),(NYSE:ABBV) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
MindMed to Participate in the Leerink Partners 2024 Global Biopharma Conference
From MindMed
Via Business Wire
News headline image
Mind Medicine (MindMed) Inc. Announces Pricing of Underwritten Offering of Common Shares and Concurrent Private Placement
From Mind Medicine (MindMed) Inc.
Via Business Wire
News headline image
MindMed Receives FDA Breakthrough Therapy Designation and Announces Positive 12-Week Durability Data From Phase 2B Study of MM120 for Generalized Anxiety Disorder
From Mind Medicine (MindMed) Inc.
Via Business Wire
News headline image
MindMed to Host Conference Call and Webcast to Discuss Data Update for MM120
From MindMed
Via Business Wire
News headline image
MindMed Reports 2023 Financial Results and Business Updates
From MindMed
Via Business Wire
News headline image
MindMed to Host Conference Call and Webcast to Discuss 2023 Financial Results and Provide Business Update
From MindMed
Via Business Wire
News headline image
MindMed to Participate in the 34th Annual Oppenheimer Healthcare Life Sciences Conference
From MindMed
Via Business Wire
News headline image
MindMed Announces Business Update and Anticipated Milestones for 2024
From Mind Medicine (MindMed) Inc.
Via Business Wire
How Psychedelic-Based Therapeutics Are Advancing in Treating Generalized Anxiety Disorder (GAD) Condition
EQNX::TICKER_START (NYSE:CYBN),(NASDAQ:CMPS),(NASDAQ:MNMD),(NASDAQ:SEEL),(NASDAQ:ATAI) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
MindMed Announces Positive Topline Results from Phase 2b Trial of MM-120 in Generalized Anxiety Disorder
From Mind Medicine
Via Business Wire
News headline image
MindMed Reports Third Quarter 2023 Financial Results and Business Highlights
From Mind Medicine
Via Business Wire
News headline image
MindMed to Host Conference Call and Webcast to Discuss Third Quarter 2023 Financial Results and Provide Business Update
From Mind Medicine (MindMed) Inc.
Via Business Wire
News headline image
MindMed Completes Enrollment of Phase 2a Trial of MM-120 in Adults with Attention-Deficit/Hyperactivity Disorder (ADHD)
From Mind Medicine Inc.
Via Business Wire
News headline image
MindMed to Present Data on the Preclinical Activity of MM-402 at the 36th Annual European College of Neuropsychopharmacology (ECNP) Congress
From Mind Medicine Inc
Via Business Wire
News headline image
Demand for Abuse Deterrent Formulation Technology Skyrocketing as Opiate Abuse is on the Rise
EQNX::TICKER_START (NASDAQ:NTRB),(NASDAQ:CMND),(NASDAQ:MNMD),(NYSE:CYBN),(NYSE:LLY) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Death Intellectual Property
The Breakthrough Therapy Aiming To Solve The World’s Mental Health Crisis
EQNX::TICKER_START (NYSE:JNJ),(NYSE:ABBV),(NASDAQ:ATAI),(NASDAQ:CMPS),(NASDAQ:MNMD) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Economy
News headline image
MindMed to Participate in the TD Cowen 3rd Annual Novel Mechanisms in Neuropsychiatry Summit
From MindMed
Via Business Wire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.